USPTO serial 99328453
TERNS
Reviewed by CopyMark Law Group
Status 730Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- MCBRIDE, CAMERON L
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with TERNS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $648*
Plus Government fees of $300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Tiffany D. Gehrke
Tiffany D. Gehrke Marshall, Gerstein & Borun LLP233 South Wacker Drive, Suite 6300Chicago, IL 60606United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, namely, small-molecule drugs for the treatment of cancer, metabolic disorders, and endocrine disorders; Pharmaceutical and biologic preparations for use in the treatment of oncology-related diseases and disorders; Pharmaceutical and biologic preparations for use in the treatment of metabolic-related diseases and disorders; Pharmaceutical and biologic preparations for use in the treatment of endocrine-related diseases and disorders; Pharmaceutical and biologic preparations for use in the treatment of diabetes and obesity-related diseases and disorders; Peptides for pharmaceutical purposes, namely, for the treatment of cancer, metabolic disorders, and endocrine disorders | ACTIVE | — |
| 042 | Pharmaceutical and biologic drug development services, namely, development of small-molecule drugs for use in humans; Pharmaceutical and biologic drug development services, namely, development of pharmaceutical and biologic preparations for the treatment of oncology-related diseases and disorders; Pharmaceutical and biologic drug development services, namely, development of pharmaceutical and biologic preparations for the treatment of metabolic-related diseases and disorders; Pharmaceutical and biologic drug development services, namely, development of pharmaceutical and biologic preparations for the treatment of endocrine-related diseases and disorders; Pharmaceutical and biologic drug development services, namely, development of pharmaceutical and biologic preparations for the treatment of diabetes and obesity-related diseases and disorders; Research and development services in the field of pharmaceutical and biologic preparations; Research and development services in the field of oncology-related diseases and disorders; Research and development services in the field of metabolic-related diseases and disorders; Research and development services in the field of endocrine-related diseases and disorders; Research and development services in the fields of diabetes and obesity-related diseases and disorders; Research and development services in the field of peptide pharmaceutical preparations; Providing medical and scientific research information in the field of small-molecule drugs; Providing medical and scientific research information in the field of clinical trials and post-market trials; Providing medical and scientific research information in the field of oncology, metabolic, endocrine, diabetes, and obesity-related diseases and disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 6, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 5, 2026 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Oct 5, 2026 | EXT1 | SOU EXTENSION 1 FILED | — |
| Oct 5, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 7, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Feb 10, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 10, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 4, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 15, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 8, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 7, 2026 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jan 7, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 8, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 8, 2025 | NWAP | NEW APPLICATION ENTERED | — |